The latest price target for Zomedica (AMEX:ZOM) was reported by Dawson James on January 6, 2023. The analyst firm set a price target for $6.00 expecting ZOM to fall to within 12 months (a possible NaN% downside). 0 analyst firms have reported ratings in the last year.

The latest analyst rating for Zomedica (AMEX:ZOM) was provided by Dawson James, and Zomedica initiated their buy rating.

There is no last upgrade for Zomedica

There is no last downgrade for Zomedica.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Zomedica, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Zomedica was filed on January 6, 2023 so you should expect the next rating to be made available sometime around January 6, 2024.

While ratings are subjective and will change, the latest Zomedica (ZOM) rating was a initiated with a price target of $0.00 to $6.00. The current price Zomedica (ZOM) is trading at is $undefined, which is out of the analyst’s predicted range.